Over the last few years, GLP-1 drugs such as Ozempic, Wegovy, and Mounjaro have taken the world by storm and helped millions of people achieve significant weight loss
And the companies behind these drugs have generated substantial revenue — more than $159 billion in less than 10 years
As a result, their stocks have seen significant gains. In one year
…Novo Nordisk — the company behind Ozempic and Wegovy — shot up 82%
…while Eli Lilly — the company behind Mounjaro — soared 98%
And these are companies that had massive market caps before making those gains — $445 billion for Eli Lilly and $358 billion for Novo Nordisk
Yet both of them nearly doubled their market caps — delivering significant returns to their shareholders.
You’ve probably heard of “Ozempic face” — the term doctors and patients use to describe the hollowed, sagging look that can appear when people lose weight very quickly using these breakthrough new drugs
It’s no fun and patients hate it — so they’re seeking solutions. Many of them are turning to Botox, fillers, and biostimulators… but the results are less than satisfying and wear off quickly
Despite that, Boston Consulting Group estimates that over the next five years, individuals will spend more than $2 billion on these solutions
And that has opened up a massive opportunity for a little-known company I’ve uncovered called Conexeu Sciences (Nasdaq: CNXU).
Conexeu has developed a new regenerative technology designed to support and rebuild facial tissue to help address the effects of Ozempic face
And based on available data and research, it may offer longer-lasting support than Botox, fillers, and biostimulators.
More importantly, it is currently the only company with this technology, which could position it to capture a significant share of this emerging market.
And that could present a noteworthy opportunity for the company and its investors, though all investments carry risk
My name is Robert Kiyosaki, creator of the hugely influential Rich Dad, Poor Dad franchise.
In recent years, I’ve devoted myself to helping ordinary investors identify major wealth trends — before they become obvious to the general public — so they can potentially reap the rewards that come from getting an early jump on those trends
My analysis suggests that treating Ozempic face is rapidly becoming one of those trends… and that Conexeu Sciences (Nasdaq: CNXU) may be well-positioned within this space
You can get all the details in a new Special Report I recently put together. It’s called The Tissue Wall Street Can’t Print, and it reveals all the reasons why I’m so excited about this unique company and the opportunity it represents
To get your free, no-obligation copy of this $199.95-value Report, click here, and you can download it immediately
According to my research and analysis, Conexeu Sciences (Nasdaq: CNXU) may represent a compelling opportunity within this emerging sector focused on helping people address Ozempic face.
And I’m already recommending that subscribers to my Kiyosaki Letter take a close look at the company. I recommend you do the same
Robert Kiyosaki is not securities dealers or brokers, investment advisers or financial advisers, and you should not rely on the information herein as investment advice. Conexeu Sciences Inc. has paid Robert Kiyosaki a fee of $125,000 as consideration for marketing services to be provided over a term of 90 days. [Robert Kiyosaki is a non-arm's-length party who owns zero common shares of Conexeu Sciences Inc.] This newsletter is for informational purposes only. This does not constitute an offer to sell or a solicitation of an offer to buy any securities, nor does it constitute investment, legal, or tax advice. Prospective investors should consult qualified legal, financial, and tax advisors before making any investment decision. The securities issued by the companies we profile should be considered high risk. If you do invest despite these warnings, you may lose your entire investment. Please do your own research before investing, including reading the companies’ SEC and SEDAR+ filings, press releases, and risk disclosures. We also recommend reviewing any applicable prospectus or offering memorandum filed by the company. The information contained in this newsletter was obtained from the company directly, as well as from SEC and SEDAR+ filings, company websites, and other publicly available sources. While we believe such information to be accurate and reliable, we cannot guarantee its accuracy and prospective investors should conduct their own due diligence.
Forward Looking Statements
This newsletter includes certain statements that may be deemed “forward looking statements”. All statements in this newsletter, other than statements of historical facts, that address events or developments that Conexeu Sciences Inc. (the “Company” or “CXU”) expects to occur, are forward looking statements. Forward looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects”, “plans”, “anticipates”, “believes”, “intends”, “estimates”, “projects”, “potential” and similar expressions, or that events or conditions “will”, “would”, “may”, “could” or “should” occur.
Forward-looking statements include, but are not limited to, statements regarding: the Company's plans to seek regulatory clearance or approval for its CXU™ product candidates across its target indications, including wound care, dental soft tissue regeneration, veterinary wound care, and medical aesthetics; the Company's anticipated timelines for regulatory submissions, clinical programs, and commercial market entry across its target verticals; the Company's belief that its regulatory strategy will compress timelines and reduce costs relative to alternative regulatory pathways; the Company's expectation that its CXU™ platform is designed to extend across multiple indications from one core formulation; the Company's expectation regarding the manufacturing, storage, and logistical advantages of its product format, including ambient storage capability, point-of-care reconstitution, and global scalability; the Company's beliefs, based on preclinical data, regarding the performance characteristics and clinical potential of its CXU™ product candidates; the Company's expectation regarding its competitive positioning and potential in the medical aesthetics and regenerative medicine markets; and the Company's estimates regarding the size of the total addressable markets across its target verticals.
Forward-looking statements are subject to a variety of known and unknown risks, uncertainties, and other factors that could cause actual events or results to differ from those expressed or implied. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Certain important factors that could cause actual results, performance or achievements to differ materially from those in the forward-looking statements include, among others: additional capital requirements; inability to obtain sufficient funding; no history of commercial operations; no operating revenues; global financial conditions; regulatory risks, including the risk that applicable regulatory authorities do not grant clearance or approval for the Company's product candidates on anticipated timelines or at all; risks related to research and development activities and the uncertainty of their outcomes; manufacturing and supply chain risks; intellectual property risks; commodity markets; insured and uninsured risks; health, safety and community relations; environmental risks and hazards; currency rate risk; infrastructure; competitive industry environment; government regulation; management and organizational growth; climate change and climate change regulations; risk of litigation; reliance on key personnel; internal controls; conflicts of interest; interest rate risk; credit risk; liquidity risk; risks related to commercialization of the Company's products, including market acceptance, pricing, and reimbursement risks; competition from existing and new market entrants; and uninsurable risks.
Preclinical Status
The CXU™ device candidate is investigational. Statements regarding its mechanism, performance, or potential are based on preclinical findings; clinical significance has not yet been established. The Company has applied to pursue FDA clearance through the 510(k) pathway as a Class II device. There can be no assurance that the Company will obtain clearance on its anticipated timeline, or at all.
This message is a PAID ADVERTISEMENT for Conexeu Sciences Inc (NASDAQ: CNXU) from Creative Direct Marketing Group, Inc. StockEarnings, Inc. has received a fixed fee of Seventy Five Hundred USD from Creative Direct Marketing Group, Inc for multiple Dedicated Email Sends, Newsletter Sponsorships and SMS Sends between Aug 19, 2026 and Aug 25, 2026. Other than the compensation received for this advertisement sent to subscribers, StockEarnings and its principals are not affiliated with either Conexeu Sciences Inc (NASDAQ: CNXU) or Creative Direct Marketing Group, Inc. StockEarnings and its principals do not own any of the stocks mentioned in this email or in the article that this email links to. Neither StockEarnings nor its principals are FINRA-registered broker-dealers or investment advisers. The content of this email should not be taken as advice, an endorsement, or a recommendation from StockEarnings to buy or sell any security. StockEarnings has not evaluated the accuracy of any claims made in this advertisement. StockEarnings recommends that investors do their own independent research and consult with a qualified investment professional before buying or selling any security. Investing is inherently risky. Past-performance is not indicative of future results. Please see the disclaimer regarding Conexeu Sciences Inc (NASDAQ: CNXU) on TheInvestmentJournal website for additional information about the relationship between Creative Direct Marketing Group, Inc and Conexeu Sciences Inc (NASDAQ: CNXU).
Today’s editorial pick for you
Fabrinet’s $1.3 Billion Quarter Has A $4.2 Million Surprise
And yet the market’s reaction on was almost comically disconnected from the strength of the headline numbers: Fabrinet (NYSE: FN) closed at $598.58, up 4.97%, before falling to about $556.27 after hours, a roughly 7% reversal.
I don’t think the after-hours reversal is a verdict on Fabrinet’s demand story. It looks more like the market has spotted a bill coming due.
Alexander Green bought Apple in 1996 — a decade before the iPhone. He recommended Nvidia at 66 cents split-adjusted in 2004. Bought Amazon and Netflix under $3 in 2005.
Now he's found three AI stocks he believes could be the most profitable investments of the next decade.
Fabrinet’s AI Surge Is Demanding A Much Bigger Investment
The eye-catching part of Fabrinet’s $4.64 billion fiscal 2026 is not just how much revenue it produced, but how much capital the company had to put behind that growth: $252.5 million in capital expenditures, more than double the $121.1 million spent in FY25. That spending helped push FY26 free cash flow down to just $4.2 million, from $207.3 million a year earlier.
That is a hell of a commitment to make in one year, but the rest of the balance sheet gives us some context. Inventory climbed from $581 million to $1.02 billion, while accounts receivable increased from $759 million to $1.02 billion. Fabrinet is clearly putting more resources into the business ahead of the demand it expects to serve.
And management isn’t behaving like the boom is about to disappear. Q1 FY27 guidance calls for $1.375 billion to $1.425 billion in revenue, which would put the company on pace for another record quarter.
The spending makes more sense when you look at what Fabrinet is preparing for: more capacity, more inventory and a larger operation built to handle the demand coming from its customers. Investors now need that investment to translate into substantially more earnings and cash flow before the price tag starts looking attractive.
Wall Street Is Starting To Treat Fabrinet Like An AI Stock
The market has spent months repricing Fabrinet as investors realize just how much of the AI infrastructure buildout runs through optical connectivity, and that recognition is now showing up in the analyst narrative around the stock. Yahoo Finance’s “13 Best Strong Buy AI Stocks” list? included Fabrinet among its picks, while others argued that the stock may already be approaching fair value after its enormous multi-year run.
I think both views tell us that FN is no longer being valued like an obscure contract manufacturer that happens to benefit from AI spending. Investors are beginning to price it as one of the infrastructure companies that could keep feeding the expansion of data centers, optical networks and high-performance computing.
The underlying business gives them a reason to do it. Fabrinet’s Q4 growth came as optical communications and other high-complexity manufacturing programs continued expanding, while management said multiple significant growth drivers are contributing to the momentum heading into FY27.
That follows a trend already visible in the previous quarter, when Fabrinet reported $1.214 billion of revenue, up 39%, with data-center interconnect revenue reaching $196.9 million, up 90% year over year.
At the same time, it makes OSI Systems (NASDAQ: OSIS)worth watching as the next data point for the broader electronics and advanced-manufacturing space, with its June-quarter results due August 20 and consensus calling for $3.76 in EPS. Of course, OSI is one of the other stocks operating in Fabrinet’s broader industry group. But the point isn’t that OSI and Fabrinet are interchangeable businesses. They aren’t. It’s that another set of results will give investors a useful read on whether the strength we’re seeing across these specialized manufacturing and infrastructure businesses is broadening.
So I don’t think the AI angle is some convenient story being attached to FN after a good earnings report. The business has been moving toward it quarter after quarter, and the market is finally catching up.
That creates a much tougher standard for the stock from here: when investors start giving a manufacturing company an AI-growth multiple, execution has to keep outrunning expectations.
FN Just Reclaimed All Three Major Moving Averages
The chart is actually much stronger than the after-hours reaction makes it look. Fabrinet closed Monday at $598.58, putting the stock comfortably above its 20-day moving average at $511.01, 50-day at $529.70 and 200-day at $537.36, with 1.59 million shares changing hands during the session.
That is a meaningful technical reset after FN spent much of the summer sliding from the $700 area toward the low $400s. The stock has now recovered sharply from that June-July washout, pushed back through the 200-day average and is approaching the $600 area, where the next real test begins.
I would pay particular attention to what happens if the after-hours weakness carries into the next session. Holding the $537-$530 zone would keep the recent recovery intact and turn those moving averages into support; falling back through them would tell us the market wasn’t ready to sustain the post-earnings optimism.
For now, the chart is still leaning bullish. The market may have taken some money off the table after the earnings release, but it hasn’t broken the underlying recovery in FN.
Bullish, Not Blind To The Price
I’m bullish on what Fabrinet is building, but I’m not going to pretend the stock is asking investors for nothing in return.
The business has earned the right to be taken seriously as a major beneficiary of the optical infrastructure buildout, and the FY27 outlook gives me little reason to think that growth is about to disappear.
What keeps me from getting carried away is the valuation and the cash conversion. Fabrinet now has to prove that the enormous investment it is making can produce enough incremental earnings and cash to justify the expectations attached to the stock.
Today’s editorial pick for you
Home Depot Posts Strong Quarter Despite “Frozen” Housing Market
Posted On Aug 18, 2026 by Ian Cooper
Home Depot (NYSE: HD) had a strong second quarter, beating Wall Street’s expectations for both sales and earnings. The company also kept its full-year financial forecast unchanged.
Table of Contents
The results are a positive sign for the home improvement retailer, which has been dealing with a tough housing market. High mortgage rates, low home sales and economic uncertainty have caused many customers to delay large home improvement projects.
“We continue to operate in what I call ‘frozen housing market’ conditions,” Chief Financial Officer Richard McPhail told CNBC. He said Home Depot is still gaining market share and improving the way it serves customers.
Home Depot reported $47.86 billion in revenue for its fiscal second quarter. That was higher than the $47.27 billion analysts had expected. The company also reported adjusted earnings of $4.92 per share, beating the $4.73 analysts had predicted.
Net income increased to $4.77 billion, or $4.79 per share, compared with $4.55 billion, or $4.58 per share, a year earlier. Revenue increased 5.7% from the same period last year. Another positive sign was Home Depot’s comparable sales, which increased 1.7%. Analysts had expected an increase of only 0.9%. McPhail said this was Home Depot’s best comparable-sales result since the third quarter of fiscal 2022.
Customers are still being careful, though
Although the results were better than expected, Home Depot says customers remain cautious about spending money on large projects. McPhail said customers generally have the money to spend but are worried about inflation, fuel costs and economic uncertainty. Those concerns are making people think twice before starting expensive renovations.
“They’ve told us they have the means to spend; they’re just hesitant,” McPhail said. For example, a customer may still be willing to buy paint, tools, or smaller home improvement items. However, they may delay a much more expensive project, such as remodeling a kitchen or bathroom.
Home Depot has seen customers continue to shop across many different categories. Both professional contractors and do-it-yourself customers remained active during the quarter.
However, the company has not yet seen a major return to large projects.
Housing market remains a challenge
The housing market continues to be one of Home Depot’s biggest challenges.
Higher mortgage rates have made buying a home more expensive. At the same time, fewer people are selling their homes. This has created what Home Depot calls a “frozen” housing market. Normally, people who buy a new home often spend money making improvements or renovations. When fewer homes are being bought and sold, there are fewer opportunities for that type of spending.
Home Depot is trying to make up for some of this weakness by focusing more on professional customers, including contractors and builders. The company believes these customers can provide a more stable source of business, even when the broader economy is uncertain.
Home Depot keeps its 2026 forecast
Even with the strong second-quarter results, Home Depot did not raise its financial forecast for the year. The company still expects total sales to grow between 2.5% and 4.5% in fiscal 2026. It also expects an operating margin between 12.4% and 12.6%.
The decision to keep its forecast unchanged shows that the company remains cautious about the rest of the year. While customers are still spending, Home Depot does not know when they will feel comfortable taking on bigger projects.
CEO takes temporary medical leave
Home Depot is also dealing with a leadership change. Last week, the company announced that CEO Ted Decker would take a temporary medical leave of absence for several months. While Decker is away, Ann-Marie Campbell, Home Depot’s senior executive vice president of U.S. stores and operations, will oversee the company’s day-to-day operations.
Despite the leadership change and challenges in the housing market, Home Depot says it plans to keep investing in its business. “We’re focused on controlling what we can control,” McPhail said. The company believes that continued investment in its stores, employees and customer service will help it gain market share now and prepare for stronger demand in the future.
For now, Home Depot’s latest results show that customers are still willing to spend on their homes, even if they are being careful about larger purchases. The company’s strong sales and earnings suggest its strategy is working, but a bigger recovery in home improvement spending may depend on the housing market and consumer confidence improving.
0 التعليقات:
إرسال تعليق